Community/Retail

The findings highlight the critical role played by excess visceral adiposity in the progression of fibrosis among HIV-infected patients with nonalcoholic fatty liver disease, according to the study authors.

Top news of the week from Pharmacy Times surrounding the novel coronavirus.

The General Pharmaceutical Council has made plans to temporarily re-register pharmacists and pharmacy technicians should the government launch a state of emergency due to the novel coronavirus.

Researchers in Australia tested blood samples at 4 different time points in an otherwise healthy adult woman who presented with COVID-19 and had mild-to-moderate symptoms requiring hospital admission.

This will be the first global study of tocilizumab in this setting and is expected to begin enrolling in early April, with a target of approximately 330 patients globally.

Although preventive measures may be largely the same for patients with cancer during the COVID-19, the pandemic could result in difficult treatment decisions.

Members of AHIP will take steps to ensure affordable access to COVID-19 testing and treatment, according to a statement from the company.

With the publication of the new vancomycin guidelines, pharmacists are going to experience a major change from trough-based monitoring of vancomycin to area under the curve-based dosing strategies.

Earlier this week, the FDA updated its guidance on testing for the novel coronavirus (COVID-19), allowing clinical laboratories to create and perform COVID-19 tests without pursuing FDA emergency use authorization (EUA).

Furthermore, they established that 101 out of every 10,000 cases will develop symptoms after 14 days of active monitoring or quarantine.

The researchers found that the average yearly out-of-pocket spending by patients with diabetes is over $1,800.

The American Pharmacists Association (APhA) is calling upon the federal Coronavirus Task Force to make greater use of pharmacists in combating the novel coronavirus (COVID-19) outbreak.

SARS-CoV-2 was detectable in aerosols for up to 3 hours, up to 4 hours on copper, up to 24 hours on cardboard, and up to 3 days on plastic and stainless steel.

The availability of personal protective equipment, including face masks, gloves and hand sanitizers, have been a concern to many pharmacists.

Value-added pharmacy services come in all shapes and sizes.

Pharmacy giants Walgreens and CVS are taking extensive steps to ensure patient access to medications during the novel coronavirus (COVID-19) pandemic, including waiving drug delivery fees and expanding telehealth options.

The approval allows Florida to waive certain requirements in Medicare, Medicaid, and CHIP.

Researchers and senior physicians support a French official’s warning that individuals showing symptoms of the novel coronavirus should use paracetamol rather than ibuprofen.

Some pharmacists and technicians are reporting that they don’t have enough personal protective equipment behind the counter.

Recently, many providers have become worried about the potential of certain medications to worsen transmission and outcomes in the setting of the global COVID-19 pandemic.

Patients who received an opioid after tooth extraction reported higher levels of pain than patients who received a non-opioid.

Conferences such as the American Pharmacists Association (APhA) 2020 Annual Meeting and Expo are now implementing virtual versions of their programs.

Although vaccine development is underway, the process can take at least a year before reaching in the mass-production stage.

West Virginia legislature passes a bill that will affect reimbursement for services that fall within a pharmacist’s purview and are ordinarily provided by other health care providers.

More than 10% of COVID-19 patients were infected by an asymptomatic person, according to new research.

The goals of the expansion are to maintain social distancing and to avoid overburdening hospitals with patients.

A 72-week interim analysis of observational data from the ongoing SEARCH study was used to examine optimal strategies for PrEP engagement and uptake after population-level HIV testing and universal PrEP access.

A clinical program evaluating sarilumab (Kevzara, Sanofi and Regeneron) has started in patients hospitalized with a severe form of the novel coronavirus (COVID-19), according to the company.